Rhythm Pharmaceuticals is a healthcare company focused on developing and commercializing innovative therapies for rare genetic disorders related to obesity. Its core product is setmelanotide, which targets the melanocortin-4 receptor pathway to address conditions such as POMC deficiency and LEPR deficiency. The company primarily generates revenue through product sales and is engaged in ongoing clinical trials to expand its treatment offerings.
The investment profile of Rhythm Pharmaceuticals is more aligned with growth investors, given its focus on innovative therapies and potential for future revenue expansion. The company is in a developmental stage, which may appeal to those seeking capital appreciation rather than immediate income.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-10-17 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-10-09 | Sell | Hold | Weak momentum and high risk limit upside potential. |
| 2026-09-21 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-09-14 | Sell | Hold | Positive revenue growth, but negative EPS and high risk. |
| 2026-09-06 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-08-29 | Buy | Hold | Weak momentum and high risk; cautious approach advised. |
| 2026-08-07 | Sell | Buy | Strong revenue growth and positive momentum indicators. |
| 2026-08-05 | Hold | Sell | Weak fundamentals and high risk limit upside potential. |
| 2026-07-28 | — | Hold | Weak fundamentals and high risk limit upside potential. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-10-12 | H.C. Wainwright | Target Raised | — → 130 | 90.78 |
| 2026-10-08 | RBC Capital | Target Raised | 155 → 159 | 87.692 |
| 2026-08-28 | Deutsche Bank | Update | — → 120 | 112.53 |
| 2026-08-05 | Canaccord Genuity | Target Raised | 151 → 154 | 105.78 |
| 2026-08-05 | National Bank | Target Raised | — → 160 | 105.78 |
| 2026-07-07 | RBC Capital | Target Raised | 137 → 141 | 111.68 |
| 2026-06-16 | Canaccord Genuity | Target Raised | — → 151 | 89.7 |
| 2026-06-15 | Stifel Nicolaus | Update | — → 133 | 94.7336 |
| 2026-06-15 | Wells Fargo | Target Raised | 144 → 155 | 88.38 |
| 2026-05-07 | Canaccord Genuity | Target Raised | 140 → 143 | 96.61 |
| 2026-03-12 | Telsey Advisory | Target Raised | — → 143 | 90.02 |
| 2026-03-12 | Wells Fargo | Target Raised | — → 143 | 90.02 |
| 2026-03-03 | Jefferies | Update | — → 125 | 89.56 |
| 2026-02-26 | Stifel Nicolaus | Update | — → 131 | 99.54 |
| 2026-02-18 | RBC Capital | Update | — → 145 | 101.3 |
